SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is experiencing significant volatility driven by reports of potential diplomatic shifts regarding the Iran conflict, sparking intense debate among traders over whether these developments signal a genuine de-escalation or just another short-term market manipulation. Community sentiment remains deeply polarized, with many market participants expressing skepticism toward overnight price action and warning of a potential 'pump and dump' as concerns persist over energy supply chains and the geopolitical implications of the Strait of Hormuz remaining closed.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is experiencing intense volatility as investors react to the escalating geopolitical conflict in the Middle East and reports suggesting a shift in U.S. military objectives. Market participants are actively debating the potential for a snapback rally versus further downside, with sentiment heavily influenced by concerns over oil prices and skepticism regarding official statements.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot (DRB) is generating significant community buzz due to its unique association with the Grok AI ecosystem and its integration with the Bankr protocol on the Base chain. Investors are highlighting the project's perceived undervaluation and AI-driven origins, leading to active social media discussion about its potential as a sleeper opportunity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending as shareholders react to a recent FDA warning letter and subsequent class-action lawsuit filings, fueling intense debate between long-term investors focused on global expansion and short-term traders concerned about volatility. The community is actively weighing the potential for international revenue from Saudi Arabia and Europe against concerns regarding domestic regulatory hurdles, while discussing whether the current price action represents a buying opportunity or a deeper correction.

Maul Coin

Maul Coin is trending as the community rallies behind the creator's mission to build an organic, transparent project that resists typical whale manipulation. Investors are actively discussing the coin's growth potential, coordinating to get it listed on charting platforms, and emphasizing a 'hold' strategy to achieve long-term appreciation.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

Market volatility is being driven by conflicting headlines regarding a potential ceasefire and diplomatic negotiations with Iran, keeping traders on edge as they weigh ongoing military maneuvers against optimistic headlines. Community sentiment is deeply divided, with many participants expressing skepticism over the legitimacy of news reports and actively debating whether current price action represents a genuine reversal or another tactical trap.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as market sentiment shifts to recognize its significant role as a primary beneficiary of the global LNG supply shortage caused by infrastructure damage in the Middle East. The community is actively discussing a flurry of analyst upgrades, the company's aggressive capacity expansion, and the long-term structural demand for reliable energy, while closely monitoring ongoing geopolitical tensions and potential settlement news as key catalysts for further growth.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as investors grapple with escalating tensions in the Middle East and conflicting reports regarding potential diplomatic resolutions. The community is actively debating whether ongoing military posturing and threats of infrastructure strikes signal a prolonged energy supply shock or if market volatility is being driven by speculative trading and political rhetoric.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is currently at the center of intense market volatility, driven by heightened geopolitical tensions in the Middle East and conflicting reports regarding potential ceasefires. Retail traders remain deeply divided, with many debating the impact of energy price fluctuations on broader indices while others speculate on the potential for aggressive short squeezes amid extreme market sentiment.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is trending as its community highlights the project's unique supply control, specifically the voluntary locking of a significant portion of its token supply in a dedicated "Airlock." Supporters are actively discussing its long-term accumulation phase, comparing its structured treasury and cult-like conviction to typical short-lived Solana memecoins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,830,724 shares...

KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) saw a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 975,765 shares, a growth...

AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. $KALA, $TGNT, $DOMO, $TSSI, $CYN, $AUNA, $VACHU

<ul class="summary-bullets"><li>Researgency enables firms to deploy AI tools for research, clinical trials, managing regulatory documents, and tracking drug safety.</li><li>Earlier this month, KALA signed a platform development and exclusive license agreement with Younet AI for Researgency.</li><li>The company said that while it will provide the AI platform, clients retain full control and ownership of their data.</li></ul>Shares of KALA BIO Inc. (KALA) shed most of their early gains to trade 25% higher on Wednesday, after the biotech company said it expects to ship its first commercial artificial intelligence product, the Researgency.ai platform, within 14 days.Researgency enables biotech and pharmaceutical companies to design and deploy AI tools to monitor research, support clinical trials, manage regulatory documents, track drug safety, and prepare commercial launch materials.The company said the platform is now fully live following a rebrand and is designed to deploy specialized AI agents to automate complex, repetitive tasks in drug development.“We are building the Palantir for biotech. Our first agent ships in 14 days, and our team is fired up. This is the beginning of something big,” said Avi Minkowitz, CEO of Kala.&nbsp;<h2 class="st-heading-2">Partnership With Younet AI To Develop Researgency</h2>Earlier this month, KALA signed a platform development and exclusive license agreement with Younet AI for Researgency. The agreement grants KALA access to the platform for an initial 12-month period, with the option to extend in one-year terms.KALA will provide the AI platform, specialized biomedical agents, and ongoing optimization, while clients retain full control and ownership of their data. The company said the platform targets small and mid-sized biotech firms seeking secure AI tools without relying on public AI services.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/KALA_jpg_f4e658a281.webp" alt="KALA.jpg">One user expects the stock to climb above $1 this week. It is currently at $0.36.<stembedurl>https://stocktwits.com/Ozunoy/message/647231891</stembedurl>Another user believes the development is “huge,” and that the company is “just getting started.”<stembedurl>https://stocktwits.com/jengtap/message/647229239</stembedurl><a href="https://stocktwits.com/symbol/KALA">KALA shares</a> have shed around 34% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-jumps-barclays-says-market-is-underestimating-opportunity-from-new-products/cZdr3RoRIJH">HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating&nbsp;Opportunity From New Products</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

Why Did KALA Stock Surge 25% Today?

KALA BIO Inc company said that it is ready to deploy its new AI platform, Researgency, within 14 days.

Equity

The company said that it is ready to deploy its new AI platform, Researgency, within 14 days.

KALA BIO, Inc. (NASDAQ:KALA) Given Average Rating of "Hold" by Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One...

<ul class="summary-bullets"><li>A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.</li><li>A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure debts.</li><li>New turnaround-focused leadership was appointed as part of the recovery plan.</li></ul>Kala Bio surged 22% after hours on Tuesday after the company disclosed a rescue financing agreement that temporarily stabilizes its operations and averts a pending asset seizure by its lender. The move marks the company's reversal since September, when its eye disease therapy KPI-012 failed a Phase 2 trial, triggering a roughly 90% collapse in the stock and a wave of analyst downgrades.<h2 class="st-heading-2">Emergency Financing Steps In After Default</h2>The after-hours rally followed Kala’s filing detailing a sequence of events that began on Sept. 29, when Oxford Finance issued a notice of default under the company’s loan agreement and declared all obligations immediately due.&nbsp;On Oct. 19, Oxford informed Kala it intended to foreclose on all remaining assets,&nbsp;sweep all of the company’s cash, and&nbsp;restrict the use of funds to minimal payroll expenses necessary to execute the foreclosure. The same day, Kala terminated all remaining employees except those required to support Oxford’s process.Oxford later paused the foreclosure on Nov. 3 and allowed Kala to access $125,000 of previously swept cash to negotiate a potential transaction. On Nov.9, Kala executed a convertible loan agreement with investor David Lazar for $375,000 to fund&nbsp;the preparation of its quarterly filing and support negotiations for further investment.<h2 class="st-heading-2">Lifeline Private Placement Up To $6 Million</h2>The company then entered into a securities purchase agreement on Nov. 23 under which Lazar agreed to provide up to $6 million in a two-stage private placement of Series AA and Series AAA preferred stock. The first closing occurred on Monday, delivering $1.8 million to Kala. The second closing, for an additional $4.2 million, requires shareholder approval to increase authorized common shares and permit conversion of the preferred stock. Kala will hold the shareholder meeting before March 31, 2026. The proceeds will fund current operations, liabilities, and expenses, with $1 million of the second closing earmarked for Oxford as part of the settlement arrangement.<h2 class="st-heading-2">Settlement Restructures Obligations</h2>As part of the rescue package, Kala and unit Combangio entered into a loan settlement agreement with Oxford on Nov. 23. Oxford agreed to settle all outstanding payment obligations in exchange for a $2 million cash settlement and 1.62 million shares of common stock.&nbsp;Once Kala pays the initial $1 million and issues the settlement shares, Oxford will release control of Kala’s bank accounts, reduce the outstanding loan balance by $7 million, and waive associated interest and final payments. The company also agreed to pay Oxford 10% of future equity financing proceeds, up to $1 million, with each such payment reducing loan obligations by 3x the amount contributed.Oxford’s foreclosure efforts will formally end once the full settlement payment is completed. Kala is committed to pursuing a “material strategic alternative transaction” within one year to clear the remaining settlement balance.<h2 class="st-heading-2">Leadership Changes Accompany Restructuring</h2>As part of the financing deal, David Lazar was appointed CEO and elected to the board on Nov. 21. Lazar brings a turnaround-focused background to the role. He currently leads Custodian Ventures LLC and Activist Investing LLC, firms that specialize in turnaround situations involving distressed public companies.Todd Bazemore, the prior CEO, stepped down from the role but remains on the board. Meanwhile, chief financial officer Mary Reumuth was terminated effective immediately following the first closing, and the company also announced settlement agreements for certain former executives tied to their contractual severence rights.<h2 class="st-heading-2">Fallout From Eye Drug Trial Failure</h2>The crisis began in late September when KPI-012, a treatment for persistent corneal epithelial defect, failed to meet all primary and secondary endpoints in the Phase 2b CHASE trial. The miss contradicted the positive signals seen in the earlier Phase 1b trial and led management to terminate development of KPI-012 and its broader mesenchymal stem cell secretome platform. Analysts at Mizuho, H.C. Wainwright and LifeSci Capital downgraded the stock immediately afterward, citing the unexpected data and lack of disclosed details.&nbsp;<h2 class="st-heading-2">Stocktwits Users Cite David Lazar Upside For Kala Bio</h2>On Stocktwits, retail sentiment for Kala Bio was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/140;" src="https://news.stocktwits-cdn.com/kala_ss_png_9a4902a4d7.webp" alt="kala ss.png" width="970" height="140"><figcaption>KALA sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One bullish user said, “<a href="https://stocktwits.com/symbol/KALA">$KALA</a> 1.50 next leg. David Lazar play. new<a href="https://stocktwits.com/symbol/CETY"> $CETY</a>.”<stembedurl>https://stocktwits.com/CAPITALWHISPERER/message/637454686</stembedurl>Another user said, “Look what david Lazzar did to $opgen and find out why he make<a href="https://stocktwits.com/symbol/KALA"> $KALA</a> investors very rich if they are patient.”<stembedurl>https://stocktwits.com/Frederickquan/message/637468005</stembedurl><a href="https://stocktwits.com/symbol/KALA">Kala Bio’s stock</a> has declined 91% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio’s stock (KALA) has declined 91% so far in 2025. (Photo credit: Getty Images)

Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse

A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

KALA BIO (KALA) announced on Monday that its KPI-012 failed in a mid-stage clinical trial evaluating it as a treatment for persistent corneal epithelial defect.A persistent corneal epithelial defect (PCED) is a corneal injury that fails to heal within the typical timeframe of two weeks, persisting for weeks or even months despite standard treatment. Kala’s study to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution did not meet the primary goal of complete healing of PCED at week 8, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.kalarx.com/news-releases/news-release-details/kala-bio-announces-topline-results-chase-phase-2b-clinical-trial">said</a>. It also noted that the secondary goals in the study did not achieve statistical significance, and there was no meaningful difference between the KPI-012 treatment arm and the placebo arm in the trial.The company subsequently decided to cease clinical development of KPI-012 and stated that it is evaluating its strategic options. The firm noted that it intends to preserve cash, including by laying off some of its workforce and implementing other cost-saving measures.Kim Brazzell, Chief Medical Officer of Kala Bio, said that the company is “disappointed” to see the new study results.“KPI-012 continued to be well-tolerated and demonstrated a favorable safety profile but did not demonstrate the efficacy results that would warrant advancing the program for treatment of front-of-the-eye diseases,” he added.Shares of the company slipped 89% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALA">KALA stock</a> rose to ‘extremely bullish’ from ‘neutral’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘high’ levels.Following the company’s announcement, LifeSci Capital downgraded Kala Pharmaceuticals to ‘Market Perform’ from ‘Outperform’ and removed the firm's price target on the stock.Mizuho analyst Graig Suvannavejh, meanwhile, expressed disappointment that the company did not share any data details or host a call to discuss the study results, as per TheFly. &nbsp;KALA stock is down by 69% this year and by about 62% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Kala Bio Stock Just Plunged 89% Today – Here’s What Happened

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

KALA
KALA BIO Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KALA News

KALAKALA BIO Inc